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Abstract 
Objective: The relationship between Human cytomegalovirus (HCMV) and glioblastoma multiforme (GBM) is 
investigated. 
Methods: A systematic review and re-analysis of some impressive key studies was conducted aimed to answer the 
following question. Is there a cause-effect relationship between HCMV and GBM? The method of the conditio 
sine qua non relationship was used to proof the hypothesis whether the presence of HCMV guarantees the presence 
of GBM. In other words, without HCMV no GBM. The mathematical formula of the causal relationship k was used 
to proof the hypothesis, whether there is a cause-effect relationship between HCMV and GBM. Significance was 
indicated by a p-value of less than 0.05.  
Results: The studies analysed were able to provide strict evidence that HCMV is a necessary condition (a conditio 
sine qua non) of GBM. Furthermore, the cause-effect relationship between HCMV and GBM (k ~ + 0.8608, p 
value < 0.0001) was highly significant. 
Conclusion: Without a human cytomegalovirus infection no glioblastoma multiforme. Human cytomegalovirus is 
the cause of glioblastoma multiforme. 
Keywords: Cytomegalovirus, Glioblastoma multiforme, Causal relationship 
1. Introduction 
Glioblastoma (Bailey & Cushing, 1926) multiforme (GBM) is a highly lethal (Zhu et al., 2002), non-curable grade 
IV diffuse astrocytoma (brain tumour) which is affecting children and adults to such an extent that to date the 
majority of affected patients are dying from their disease by 2,5 years following diagnosis (Smoll et al., 2013). 
Glioblastoma multiforme consist primarily of neoplastic astrocytes but includes also other non-neoplastic cell 
types (Yuan et al., 2004) like neural stem cells, macrophages et cetera. The commonly used World Health 
Organization (WHO) classification distinguishes different types of glioblastoma multiforme (Louis et al., 2007) 
due to the presumed cell of origin. In general, glioblastoma multiforme may first appear as a grade 4 glioblastoma 
(GBM) and is called primary GBM while secondary glioblastoma multiforme develops from a lower grade 
astrocytoma. The Cancer Genome Atlas (Verhaak et al., 2010) researchers classified four subtypes of GBM as 
Proneural, Neural, Classical, and Mesenchymal subtypes. In point of fact, even if Glioblastoma multiforme 
progresses rapidly and is fatal within a very short time despite current therapies, to date the aetiology of 
glioblastoma multiforme is completely unknown. Among several risk factors supposed to be involved in 
glioblastoma including exposure to electrical or magnetic fields or ionizing radiation (Ohgaki, 2009) human 
cytomegalovirus too has been proposed as a contributing agent of glioblastoma multiforme. To our knowledge, 
HCMV as a member of the Betaherpesvirinae subfamily (Landolfo et al., 2003) is containing a linear 
double-stranded DNA of 230 kb surrounded by a proteinaceous tegument, which itself is enclosed by a loosely 
applied lipid bilayer and contains more than 60 virus-encoded proteins and about 70 host-proteins. The proteins 
produced by the HCMV can be detected (Landolfo et al., 2003) in various human cellular compartments i.e. by 
means of immunohistochemistry (IHC). A primary human cytomegalovirus infection leads to a life-long viral 
persistence. In the latent phase of a HCMV infection HCMV virions are not produced and patients are more or less 
clinically without symptoms (Priel et al., 2015) but HCMV itself can be present in the monocytes. The 
seroprevalence of HCMV in the general human population ranges between 50 to 100% (Gandhi & Khanna, 2004; 
Ludwig & Hengel, 2009; Yi et al., 2013; Najafi et al., 2016). Even a foetus itself is not protected against a vertical 
transmission. Thus far, HCMV represents the major infectious cause of serious birth defects or developmental 
disabilities. During maternal primary infection, and to a lesser extent during recurrent infection, human 
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cytomegalovirus can translocate the placental barrier and can cause infection of the developing foetus too. Human 
cytomegalovirus is occurring in 0.5-2% of pregnancies in Europe and the United States (Kenneson et al., 2007; 
Wang et al., 2011) and neonatal infections (Fowler et al., 2018) caused by human cytomegalovirus have been 
reported too. In particular, many breast milk-acquired infections in premature infants are asymptomatic. Several 
studies demonstrated the presence of human cytomegalovirus in glioblastoma tissues suggesting that HCMV may 
participate in tumour pathogenesis. But the relationship between GBM and HCMV is controversial because many 
other studies were unable to detect HCMV in Glioblastoma multiforme tissues. 
2. Material and methods 
2.1 Material  
2.1.1 Search Strategy 
To answer the questions addressed in this paper, the electronic database PubMed was searched for appropriate 
studies conducted in any country which investigated the relationship between human cytomegalovirus and 
glioblastoma multiforme i. e. sero-epidemiologically or by polymerase chain reaction (PCR) et cetera. The search 
in PubMed was performed while using some medical key words like "case control study" and "cytomegalovirus" 
and "glioblastoma multiforme" et cetera. The articles found where saved as a *.txt file while using the support of 
PubMed. The created *.txt file was converted into a *.pdf file. The abstracts where studied within the *.pdf file. 
Those articles were considered for a re-view which provided access to data without any data access barrier. 
Additionally the reference list of identified articles was used as a potential source of articles appropriate for this 
study.  
2.1.2. The 2x2 Table 
The meaning of the abbreviations at, bt, ct, dt, Nt of the data table used are explained by a 2 by 2-table Table 1. 
 
Table 1. The sample space of a contingency table. 
  Conditioned Bt (Outcome)  
  Yes = +1 Not = +0 Total 
Condition At 
(risk factor) 
Yes =+1 at bt At 
Not = +0 ct dt At 
 Total Bt Bt Nt 
 
In general it is (at+bt) = At, (ct+dt) = At, (at+ct) = Bt, (bt+dt) = Bt and at+bt+ct+dt=Nt. Equally, it is Bt+Bt = At + At 
= Nt. In this context, it is p(at)=p(At ∩Bt), p(At) = p(at)+p(bt) or p(At)= p(At ∩Bt)+ p(bt) =p(At ∩Bt)+p(At ∩Bt) 
while p(At) is not defined as p(at). In the same context, it is p(Bt) = p(at)+p(ct) = p(At ∩Bt) +p(ct) and equally in 
the same respect p(Bt) = 1- p(Bt) =p(bt)+p(dt). Furthermore, the joint probability of At and Bt is denoted in 
general by p(At ∩Bt). Thus far, it is p(At ∩Bt) = p(At) - p(bt) = p(Bt) - p(ct) or in other words it follows clearly 
that p(Bt) + p(bt) - p(ct) = p(At). Thus far, define Λ = p(bt) - p(ct), Einstein’s term Λ under conditions of 
probability theory and we obtain p(Bt) + Λ = p(At). In general, it is p(at)+p(ct)+p(bt)+p(dt) = 1. 
2.1.3 The Studies not Analyzed  
The studies of Baumgarten et al. (2014), Holdhoff et al. (2017) and Wrensch et al. (2005) which investatigated 
the relationship between HCMV serostatus and glioblastoma patients were not considered for a review. The 
study of Yamashita et al. (2014) did not detect HCMV DNA in any of the glioblastoma cases by real-time 
quantitative PCR (QPCR). Still, while using immunoblotting and immunohistochemistry tissue samples were 
partly positive according to Yamashita et al. (2014). Thus, it remains unclear the extent to which the methods used 
by Yamashita et al. (2014) were able to detect the entire HCMV genome when present. Yang et al. (2017) 
investigated the presence of HCMV genes in human glioblastoma multiforme cases by quantitative PCR using 
inappropriate HCMV UL73. The data were not re-analyzed.  
2.1.4 The Studies Used to Analyze the Conditio Sine Qua non Relationship between HCMV and GBM  
The studies used to analyze the conditio sine qua non relationship between HCMV and GBM are viewed by the 
Table 2. 
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Table 2. Without human cytalomegalovirus infection no glioblastoma multiforme. 
Study Id Year Country N at bt ct dt p(SINE) X²(Sine) k X²(k) p val (k)
Cobbs et al. 2002 USA 45 22 0 0 23 1 0.0114 1.0000 45.0000 < 0.0001
Mitchell et al.  2008 USA 90 42 0 3 45 0.9666667 0.1389 0.9354 78.7500 < 0.0001
Scheurer et al.  2008 USA 42 21 0 0 21 1 0.0119 1.0000 42.0000 < 0.0001
Dziurzynski et al.  2011 USA 10 5 0 0 5 1 Rule of 3 1.0000 - - 
Ranganathan et al.  2012 USA 90 73 2 2 13 0.9777778 0.0300 0.8400 63.5040 < 0.0001
Rahbar et al.  2012 Sweden 160 79 0 1 80 0.99375 0.0031 0.9876 156.0494 < 0.0001
Libard et al. 2014 Sweden 86 65 0 7 14 0.9186047 0.5868 0.7758 51.7593 < 0.0001
Ding et al.  2014 China 73 51 0 16 6 0.7808219 3.5858 0.4556 15.1547 0.0001 
Wakefield et al.  2015 USA 48 14 0 10 24 0.7916667 3.7604 0.6417 19.7647 < 0.0001
Xing et al 2016 China 51 40 0 3 8 0.9411765 0.1453 0.8225 34.5032 < 0.0001
Stangherlin et al.  2016 Brazil 23 9 1 1 12 0.9565217 0.0250 0.8231 - - 
Slinger et al. 2010 Netherlands 42 20 12* 1 9* 0.9761905 0.0119 - - - 
Lucas et al.  2011 USA 90 25 25* 20 20* 0.7777778 8.4500 - - - 
Bhattacharjee et al. 2012 USA 34 16 10* 1 7* 0.9705882 0.0147 - - - 
Rahbar et al.  2013 Sweden 150 74 40* 1 35* 0.9933333 0.0033 - - - 
dos Santos et al.  2014 Brazil 44 21 12* 1 10* 0.9772727 0.0114 - - - 
Total 1078 577 102 67 332 0.9378479 16.19 
Alpha = 0.05   
Degrees of freedom (d. f.) = 15   
X² Critical (SINE) = 24.996   
X² Calculated (SINE) = 16.19   
*fictive values (due to a missing control group) 
 
The data as presented by Ranganathan et al. (2012) clearly demonstrated that HCMV genomes are associated with 
GBM tumors. Even if presentation and illustration of the data of the study of Ranganathan et al. (2012) was 
difficult to analyze, it was possible to use the data of HCMV UL69. Several of the studies presented above are 
missing an own control group. Especially the studies of dos Santos et al. (2014), Slinger et al. (2010), 
Bhattacharjee et al. (2012), Lucas et al. (2011), Holdhoff et al. (2017), Baumgarten et al. (2014) did not provide a 
suitable control group. This fact has no mathematical influence on the calculation of the chi square value of the 
necessary condition. Still, we calculated a fictive control group due to the fact that the seroprevalence of HCMV in 
the general human population ranges between 50 to 100% (Gandhi & Khanna, 2004; Ludwig & Hengel, 2009; Yi 
et al., 2013; Najafi et al., 2016). 
2.1.5 The studies Used to Analyze the Necessary and Sufficient Condition Relationship and the Causal 
Relationship Between HCMV and GBM 
 
Table 3. The necessary and sufficient condition relationship and the causal relationship between HCVM and GBM 
Study Id Year Country N at bt ct dt p(IMP^SINE) X²(IMP^SINE) k X²(k) p val (k)
Cobbs et al.  2002 USA 45 22 0 0 23 1 0.0227 1 45.00 < 0.0001
Mitchell et al.  2008 USA 90 42 0 3 45 0.966666667 0.1448 0.935 78.75 < 0.0001
Scheurer et al.  2008 USA 42 21 0 0 21 1 0.0238 1 42.00 < 0.0001
Dziurzynski et al.  2011 USA 10 5 0 0 5 1 Rule of 3 1 10.00 0.0016 
Ranganathan et al.  2012 USA 90 73 2 2 13 0.955555556 0.0600 0.84 63.50 < 0.0001
Rahbar et al.  2012 Sweden 160 79 0 1 80 0.99375 0.0063 0.9875 156.05 < 0.0001
Libard et al.  2014 Sweden 86 65 0 7 14 0.918604651 0.5907 0.7757 51.76 < 0.0001
Ding et al.  2014 China 73 51 0 16 6 0.780821918 3.5907 0.4556 15.15 0.0001 
Wakefield et al.  2015 USA 48 14 0 10 24 0.791666667 3.7783 0.6416 19.76 < 0.0001
Xing et al.  2016 China 51 40 0 3 8 0.941176471 0.1516 0.8225 34.50 < 0.0001
Stangherlin et al.  2016 Brazil 23 9 1 1 12 0.913043478 Rule of 3 0.8230 15.58 0.0001 
Total 718 421 3 43 251 0.935933148 8.3689 0.8608 532.06 
Alpha = 0.05 Alpha = 0.05 
Degrees of freedom (d. f.) = 9 Degrees of freedom (d. f.) = 11 
X² Critical (SINE^IMP) = 16.91 X² Critical (k) = 19.6751 
X² Calculated (SINE^IMP) = 8.368 X² Calculated (k) = 532.06 
p value (k) < 0.0001 
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2.2 Methods  
2.2.1 Statistical Analysis 
All statistical analyses (Barukčć. 1989; Barukčć. 2017a; Barukčć. 2017b; Barukčć. 2017c; Barukčć. 2018a; 
Barukčć. 2018b; Barukčć. 2018c) were performed with Microsoft Excel version 14.0.7166.5000 (32-Bit) 
Software (Microsoft GmbH. Munich. Germany). The level of significance was set to 0.05. The probabilities of 
the contingency table are viewed by the following table (Table 4).  
Table 4. The probabitlities of a contingency table 
  Conditioned Bt  
  Yes = +1 No = +0 Total 
Condition At Yes =+1 p(at) = p(At ∩Bt) p(bt) p(At) No = +0 p(ct) p(dt) p(At) 
 Total p(Bt) p(Bt) 1 
 
2.2.2 Independence 
In the case of independence of At and Bt it is generally valid that 
 
(1) 
 
2.2.3 Exclusion (At Excludes Bt and Vice Versa Relationship) 
The mathematical formula of the exclusion relationship (At excludes Bt and vice versa) of a population was 
defined (Barukčć, 2016a; Barukčć, 2017a; Barukčć, 2017b; Barukčć, 2017c; Barukčć, 2018a; Barukčć, 2018b; 
Barukčć, 2018c) as 
 
(2) 
 
and used to proof the hypothesis: At excludes Bt and vice versa.  
2.2.4 Necessary Condition (Conditio Sine Qua Non) 
The mathematical formula of the necessary condition relationship (conditio sine qua non) of a population was 
defined (Barukčć, 2016a; Barukčć, 2017a; Barukčć, 2017b; Barukčć, 2017c; Barukčć, 2018a; Barukčć, 2018b; 
Barukčć, 2018c) as 
 
(3) 
 
and used to proof the hypothesis: without At no Bt .  
2.2.5. Sufficient Condition (Conditio per Quam) 
The mathematical formula of the sufficient condition relationship (conditio per quam) of a population was 
defined (Barukčć, 2016a; Barukčć, 2017a; Barukčć, 2017b; Barukčć, 2017c; Barukčć, 2018a; Barukčć, 2018b; 
Barukčć, 2018c) as 
 
(4) 
 
and used to proof the hypothesis: if At then Bt .  
2.2.6 The X² Goodness of Fit Test of a Necessary Condition 
Under conditions where the chi-square goodness of fit test (Pearson, 1900) cannot be used it is possible to use an 
approximate and conservative (one sided) confidence interval known as the rule of three (Rumke, 1975; Hanley et 
( ) ( ) ( )t t t tp A B p A p B∩ ≡ ×
( ) ( ) ( ) ( ) ( ) ( )( )t t tt t t t t t t
t
a b dp A B p a p b p d p a 1 p B 1N
+ +
← ≡ ≡ + + ≡ + − ≡ +
( ) ( ) ( ) ( ) ( ) ( ) ( )( ) ( ) ( )( )t t tt t t t t t t t t t
t
b c dp A | B 1 p a p b p c p d p c 1 p B p b 1 p A 1N
+ +
≡ ≡ − ≡ + + ≡ + − ≡ + − ≡ +
( ) ( ) ( ) ( ) ( ) ( )t t tt t t t t t t
t
a c dp A B p a p c p d p d p B 1N
+ +
→ ≡ ≡ + + ≡ + ≡ +
mhs.ideasspread.org Modern Health Science Vol. 1, No. 2; 2018 
 23 Published by IDEAS SPREAD 
 
al., 1983; Louis, 1981; Jovanovic et al., 1997). According to the definition of the conditio sine qua non relationship 
it is 
(5) 
or 
 
(6) 
 
Rearranging this equation, we obtain the essential foundation of the conditio sine qua non relationship as 
 
(7) 
 
and equally our starting point of the derivation of chi-square value of the conditio sine qua non relationship. 
Multiplying equation before by the population or sample/population size N. it is 
 
(8) 
or 
(9) 
The square operation yields 
 
(10) 
 
Dividing by N×p(Bt) we obtain  
 
(11) 
which is equivalent with 
 
(12) 
 
Adding ((bt+dt) –(Bt))²/Bt = ((bt+dt) –( bt+dt))²/Bt = 0 yields 
 
(13) 
 
Using the continuity correction (Yates, 1934), the chi-square value of a conditio sine qua non distribution before 
changes to 
 
 
(14) 
 
The use of the continuity correction should follow the rules of statistics as established and valid today. This 
definition of the X² distribution of a conditio sine qua non distribution (degrees of freedom = 2-1=1) is more 
precise than already published formulas. In this context, it is not necessary to improve the definition of the X² 
distribution of a conditio per quam distribution as already published. The significance of a causal relationship k 
which is k > 0 is supported by a significant conditio sine qua non relationship; otherwise the result of a study 
should be treated with cautious. 
( ) ( )( )t t tp A B 1 p B 1∩ + − ≡ +
( ) ( )t t tp A B 1 p B 1∩ + − ≡ +
( ) ( )t t tp A B p B∩ =
( ) ( )t t tN p A B N p B× ∩ ≡ ×
( ) ( )t t tN p A B N p B 0× ∩ − × =
( ) ( )( ) ( ) ( )( )t t t t t tN p A B N p B N p A B N p B 0 0× ∩ − × × × ∩ − × = ×
( ) ( )( )
( )
2
t t t
t
N p A B N p B 0N p B
× ∩ − ×
=
×
( )( )
( )
( )( )
( )
( )
( )
2 2 2
t t t t t t
t t t
a B a a c c 0B B B
− − +
= = =
( )
( )
2
t
t
c 0 0 0B + = +
( ) ( )
2
t
2
t
1c 2SINE 0 0B
  
−     χ ≡ + =
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2.2.7 The X² Goodness of Fit Test of the Exclusion Relationship 
According to the definition of the exclusion relationship (Barukčć, 2016a; Barukčć, 2017a; Barukčć, 2017b; 
Barukčć, 2017c; Barukčć, 2018a; Barukčć, 2018b; Barukčć, 2018c) it is 
 
(15) 
Rearranging this equation, we obtain 
 
(16) 
and 
(17) 
The chi square goodness of fit test of the exclusion relationship can be derived as follows. 
 
 
 
 
 
 
 
 
 
 
(18) 
 
 
and as 
 
 
 
 
 
(19) 
 
 
 
 
 
 
The chi square value with degree of freedom 2-1=1of the exclusion relationship with a continuity correction 
(Yates, 1934) can be calculated as 
 
(20) 
 
( ) ( ) ( )t t tp b p c p d 1+ + ≡ +
( ) ( ) ( ) ( ) ( )( ) ( ) ( )tt t t t t tp b 1 p c p d 1 p c p d 1 p A p A= − − = − + ≡ − =
( ) ( ) ( ) ( ) ( )( ) ( ) ( )tt t t t t tp c 1 p b p d 1 p b p d 1 p B p B= − − ≡ − + = − =
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( ) ( )( )
( ) ( )( ) ( ) ( )( )
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A significant causal relationship k which is k < 0 is supported by an exclusion relationship otherwise the results of 
a study can be interpreted with some cautious. It would be a mistake not to consider all aspects of the relationship 
between cause and effect. Finally, it should be noted that the fundamental concepts of necessary and sufficient 
conditions is one of the handy tools which can help us to proof causal claims too. 
2.2.8 The Mathematical Formula of the Causal Relationship k 
The mathematical formula of the causal relationship k (Barukčć, 2016a; Barukčć, 2017a; Barukčć, 2017b; 
Barukčć, 2017c; Barukčć, 2018a; Barukčć, 2018b; Barukčć, 2018c; Barukčć, 2018d; Barukčć, 2018e; Barukčć, 
2018f; Barukčć, 2018g) is defined at every single event, at every single Bernoulli trial t, as 
 
(21) 
 
where At denotes the cause and Bt denotes the effect. The chi-square distribution can be applied to determine the 
significance of causal relationship k. Pearson’s concept of correlation (Pearson, 1896) is not identical with 
causation, causation (Heisenberg, 1927; Einstein & Podolsky & Rosen, 1935; Bohr, 1937; Einstein, 1948) is not 
identical with correlation. In particular, the relationship between correlation and causation has already been 
discussed in many publications (Wright, 1921; Sober, 2001). Thus far, repeating itself over and over again on this 
topic is only a waste of time and will not contribute anything new to further scientific progress. 
2.2.9 The 95% Confidence Interval of the Causal Relationship k 
A confidence interval (CI) of the causal relationship k calculated from the statistics of the observed data can help to 
estimate the true value of an unknown population parameter with a certain probability. Let the sample mean S be 
 
 
(22) 
 
Since k(At,Bt) is Bernoulli(p) distributed with E(k(At,Bt)) = (1× p(k(At,Bt))) + (0×(1- p(k(At,Bt))) = p(k(At,Bt)) 
where E(k(At,Bt)) denotes the expected value of k(At,Bt) it is 
 
(23) 
 
where σ(S)² denotes the variance of the sampling distribution of p(k(At,Bt)). When the sample size is not too small, 
the central limit theorem based normal approximation can be used to estimate the confidence interval (CI) as  
 
(24) 
 
where p(k(At,Bt)) denotes the proportion of successes in a Bernoulli trial process and Z is the (1–(α/2)) quantile of 
a standard normal distribution. For a 95% confidence level Z ~ 1.96, For an unknown standard deviation the 
Student's t distribution t can be used as the critical value. Still, it is known that σ(S)² has the maximum value 
(1/(4×n)) when p=1/2 and we have 
 (25) 
 
The proposed approximation is of use even under circumstances where p(…) = 0.9999 … 999 ~ p=1.  In this 
context, we obtain the critical value pcritical approximately as pcritical = 1 – (1/(2n))1/2.  In particular, the concept of 
Chebyshev’s inequality (Tchébychef, 1867) is profound because the same inequality is true for every distribution 
even if the distribution isn’t normal. Thus far, Chebyshev’s inequality allows calculating the 95% confidence of 
the causal relationship k and so by the Chebyshev inequality it is 
( ) ( ) ( ) ( )( )( )( ) ( )( ) ( ) ( )( )
t t t t
t t
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
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 × −   ± × ± × × −        
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(26) 
 
were the right side has the value 0.95 when c =(20)1/2. This is the case since (1-(1/c²))=0.95 or 0.05 = (1/c²) or c²= 
(1/0.05) or c² = (100/5) or c² = 20 or c =(20)1/2. Thus far, if S does lie in the interval 
 
(27) 
 
then p(k(At,Bt)) itself must be in the interval 
 
(28) 
 
which is equally the 95% confidence interval for an unknown parameter p(k(At,Bt)). Again, σ(S)² has the 
maximum value (1/(4×n)) when p=1/2, so we have  
 
(29) 
 
 
or the 95% interval for the causal relationship k as 
 
(30) 
 
2.2.10 Odds Ratio  
The odds ratio (OR) is given (Cornfield, 1951; Edwards, 1963; Mosteller, 1968) by 
 
(31) 
 
Under conditions were ct=0 we have a conditio sine qua non relationship while the odds ratio collapses. Under 
conditions were bt=0 we have a conditio per quam relationship but the odds ratio collapses again, since to date it is 
not generally accepted (Barukčić & Barukčić, 2016b; Barukčić, 2018d) to divide by zero. To avoid confusion on 
this issue, 0.5 is added to the cells at, bt, ct, dt (Pagano & Gauvreau, 2018), if zero causes some problems with the 
calculation of the odds ratio or its standard error which is often very misleading. In point of fact, the odds ratio (OR) 
is nothing more but Yule’s coefficient of association Q (Yule, 1900) re-written (Warrens, 2008) in a 
non-normalized form and given by 
 
 
(32) 
 
 
If Q = 0 then there is no association. Yule's coefficient of association, Q, and thus far Odds ratio itself, has been 
severely criticized by Karl Pearson (1857–1925), the long-time and rarely challenged leader of statistical science 
and by Heron (Pearson & Heron, 1913). The standard error and 95% confidence interval of the odds ratio (OR) can 
be calculated according to Altman (Altman, 1991). The standard error of the log odds ratio is given by 
 
 (33) 
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where ln denotes the logarithmus naturalis. The 95% confidence interval of the odds ratio is given by 
 
(34) 
2.2.11 The Chi Square Distribution 
The following critical values of the chi square distribution as visualized by Table 5 are used in this publication. 
 
Table 5. The critical values of the chi square distribution (degrees of freedom: 1) 
  p-Value One sided X² Two sided X² 
The chi 
square 
distribution 
 
0.1000000000 
0.0500000000 
0.0400000000 
0.0300000000 
0.0200000000 
0.0100000000 
0.0010000000 
0.0001000000 
0.0000100000 
0.0000010000 
0.0000001000 
0.0000000100 
0.0000000010 
0.0000000001 
1.642374415 
2.705543454 
3.06490172 
3.537384596 
4.217884588 
5.411894431 
9.549535706 
13.83108362 
18.18929348 
22.59504266 
27.03311129 
31.49455797 
35.97368894 
40.46665791 
2.705543454 
3.841458821 
4.217884588 
4.709292247 
5.411894431 
6.634896601 
10.82756617 
15.13670523 
19.51142096 
23.92812698 
28.37398736 
32.84125335 
37.32489311 
41.82145620 
 
3. Results 
3.1 Without a Human Cytomegalovirus Infection no Glioblastoma Multiforme. 
Claims. 
Null hypothesis: 
A cytomegalovirus infection is a necessary condition (a conditio sine qua non) of glioblastoma multiforme. In 
other words, the sample distribution of the study analyzed agrees with the hypothetical (theoretical) distribution 
of a necessary condition. 
Alternative Hypothesis: 
A cytomegalovirus infection is not a necessary condition (a conditio sine qua non) of glioblastoma multiforme. 
In other words, the sample distribution of the study analyzed does not agree with the hypothetical (theoretical) 
distribution of a necessary condition. 
The significance level (Alpha) below which the null hypothesis will be rejected is alpha= 0.05. 
Proof.         
The results of the re-analyses of the data reviewed by this article (Table 2) which investigated the relationship 
between a cytomegalovirus infection and glioblastoma multiforme are viewed by the table (Table 2). Altogether, 
16 studies were meta-analyzed while the level of significance was alpha = 0.05. In toto, 16 out of 16 studies 
provide significant evidence of a conditio sine qua non relationship between a cytomegalovirus infection and 
glioblastoma multiforme. The study of Dziurzynski et al. (2011) was significant according to the rule of three. 
Some of the studies were performed without a control group which had no mathematical effect on the calculation 
of the chi square value of the conditio sine qua non relationship. The most of the studies analyzed were able to 
provide evidence of a significant, positive cause effect relationship. In other words, the data analyzed support the 
Null-hypothesis: without a cytomegalovirus infection no glioblastoma multiforme (X² Calculated (SINE) = 16.19 
and is less than X² Critical (SINE) = 24.996). Q. e. d. 
3.2 HCMV is a Necessary and Sufficient Condition of Glioblastoma Multiforme 
Null Hypothesis: 
A cytomegalovirus infection is a necessary and sufficient condition of glioblastoma multiforme. In other words, 
the sample distribution of the study analyzed agrees with the hypothetical (theoretical) distribution of a necessary 
and sufficient condition.   
( )( ) ( )( )( )( )( ) ( )( ) ( )( )( )( )( )t t t t t t t t95% CI exp ln OR A ,B 1.96 SE ln OR A ,B   to  exp ln OR A ,B 1.96 SE ln OR A ,B  = − × + ×
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Alternative Hypothesis: 
A cytomegalovirus infection is not a necessary and sufficient condition of glioblastoma multiforme. In other 
words, the sample distribution of the study analyzed does not agree with the hypothetical (theoretical) 
distribution of a necessary and sufficient condition. 
The significance level (Alpha) below which the null hypothesis will be rejected is alpha=0.05.  
Proof.  
The results of the re-analyses of the data reviewed by this article (Table 2) which investigated the necessary and 
sufficient condition relationship between a cytomegalovirus infection and glioblastoma multiforme are viewed 
by the table (Table 3). Altogether, it was possible to consider 11 studies with a sample size of N=718 for a 
meta-analyzed while the level of significance was alpha = 0.05. In toto, 11 out of 11 studies provide significant 
evidence (Table 3) of a necessary and sufficient conditions relationship (X² Calculated (SINE^IMP) = 8.3689 is 
less than X² Critical (SINE^IMP) = 16.918) while the causal relationship between a cytomegalovirus infection 
and glioblastoma multiforme was positive and significant. The studies of Dziurzynski et al. (Dziurzynski et al., 
2011) and Stangherlin et al. (Stangherlin et al., 2016) were smaller than N = 30 and were analyzed according to 
the rule or three. Especially, the study of Rahbar et al. (Rahbar et al., 2012) detected HCMV-IEA in 79 (99%) of 
80 GBM tumor cells but not in surrounding non-tumor cells. In general, a cytomegalovirus infection is a 
necessary and sufficient condition of glioblastoma multiforme (Table 3). Q. e. d. 
3.3 HCMV is the Cause of Glioblastoma Multiforme 
Several studies presented missed an appropriate control groups and were not considered for the analyses of the 
causal relationship between HCMV and GBM (Table 2).  
Claims.         
Null Hypothesis:         
A cytomegalovirus infection is not the cause of glioblastoma multiforme. In other words. k = 0. 
Alternative Hypothesis:         
A cytomegalovirus infection is the cause of glioblastoma multiforme. In other words. k ≠ 0. . 
The significance level (Alpha) below which the null hypothesis will be rejected is alpha=0.05.  
Proof.         
The results of the re-analyses of the data reviewed by this article (Table 2) which investigated the causal 
relationship between a cytomegalovirus infection and glioblastoma multiforme are viewed by the table (Table 3). 
Altogether, 11 studies were meta-analyzed while the level of significance was alpha = 0.05. In toto, 11 from 11 
studies provided significant evidence of a causal relationship between a cytomegalovirus infection and 
glioblastoma multiforme. The studies of Dziurzynski et al. (2011) and Stangherlin et al. (Stangherlin et al., 2016) 
were smaller than N = 30. In the same respect, a cytomegalovirus infection is a necessary (Table 2) and a 
necessary and sufficient condition of glioblastoma multiforme (Table 3). In other words, without a HCVM 
infection no GBM. Thus far, the conclusion is inescapable. Human cytomegalovirus is the cause of glioblastoma 
multiforme (k ~ 0.8608, X² Calculated (k) =532.06 and is greater than X² Critical (k) =19.6751). Q. e. d. 
4. Discussion 
Due to the conflicting reports concerning the presence of the human cytomegalovirus in glioma tissue the 
association between human cytomegalovirus (HCMV) infection and glioblastoma is still a source of debate. While 
some studies detected HCMV DNA, RNA and proteins et cetera in GBM tissues others studies (Taha et al., 2016) 
have not. In most of the previous studies, only a very restricted number of HCMV viral targets with different 
sensitive techniques (Immunoglobulin G antibodies. immunohistochemical analysis, PCR, in situ hybridization, 
immunohistochemistry, real-time PCR et cetera ) accompanied by a very different personal skill were analysed.  
Thus, the question is justified to which extent was the (entire) viral genome detected at all when present. 
Furthermore, complicating issues are creating uncertainty about the results of the studies above which detected a 
strong relationship between HCMV with GBM tumours due to the relatively limited study population and 
non-randomization. In particular, sample quality (age or method of preservation) and primer selection has 
substantial effects on the outcome of a study. All these factors may have contributed to the few studies which were 
not able (Taha et al., 2016) to detect HCMV in GBMs tissues. In contrast to results like these, HCMV presence has 
been found in about 90-100% (Cobbs et al., 2002; Mitchell et al., 2008; Rahbar et al., 2012; Söderberg-Nauclér et 
al., 2013) of GBM tumors. Söderberg-Nauclér et al. (Söderberg-Nauclér et al., 2013) examined more than 250 
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cases of glioblastoma while only one of these patients was CMV-negative. Due to the missing control group, the 
very convincing data of the study of Söderberg-Nauclér et al. (2013) were not considered for causal analysis while 
the conditio sine qua non relationship is highly significant. Rahbar et al. (2012) detected HCMV infection in 79 of 
80 patients (99%) GBM tumor samples. The surrounding non-tumor cells of the same patient served as the control 
group. Rahbar et al. (2012) were not able to detect HCMV in any of the controls i. e. HCMV was not detected in 
surrounding non-tumor cells. The results of the study of Rahbar et al. (2012) are viewed by Table 6. The single 
study of Rahbar et al. (2012) has provided striking evidence that HCMV infection is a necessary, a sufficient and a 
necessary and sufficient condition of GBM while the cause effect relationship between HCMV and GBM is highly 
significant. Thus far and ultimately, according to the study of Rahbar et al. (2012) HCMV is the cause of GBM and 
much more than this. The evidence of the studies presented cannot be ignored too. In point of fact, several studies 
did not present a suitable control group (Table 2). Thus far, it was not possible to consider these studies to 
calculate the causal relationship k between HCVM and GBM. Besides of this limitation, the missed control group 
had no mathematical influence on the calculation of the chi square value of the necessary condition distribution. 
All but the study of Lucas et al. (2011) underdetermine empirically the Null-hypothesis: without HCVM no GBM. 
In other words, GBM cannot develop without a HCVM infection. It is obvious that the evidence of the relationship 
between HCVM and GBM is much stronger then outlined just before. In toto, 11 studies with a sample size of 
n=718 (Table 3) support the Null-hypothesis that HCMV is a necessary and sufficient condition of GBM while the 
cause effect relationship k between HCMV and GBM is highly significant (Table 3). Ultimately, the evidence 
documented is extensive, solid and sufficient to justify the hypotheses that HCMV is the cause of GBM.  
 
Table 6. The Study of Rahbar et al. (Rahbar et al., 2012) 
GBM <B> 
Yes No Total
HCMV-IEA Yes 79 0 79
<A> No 1 80 81
Total 80 80 160
k =0.98757716
p value (k) =8.258E-36
WITHOUT <A> NO <B>. 
p ( SINE ) =0.99375 
X²( SINE ) =0.003125 
IF <A> THEN <B>  
p (IMP)=1   
X² (IMP)=0.00316456
<A> is SINE and IMP of <B>
p(SINE ^ IMP) =0.99375 
X²(SINE ^ IMP) =0.00628956
 
To date, aggressive treatment (Stupp et al., 2005) of glioblastoma multiforme with surgery, radiation therapy and 
chemotherapy are relatively ineffective due to the known aggressive nature of GBM and provides only a very 
limited overall survival benefit for these patients. In fact, there is no effective therapy or cure for glioblastoma 
multiforme while the life of the patients suffering from this disease is extremely (Smoll et al., 2013) endangered. 
New therapeutic strategies should be offered to counteract the poor prognosis of GBM. HCMV is the cause of 
GBM and has a major impact on morbidity, mortality and survival of GBM patients too. In this context, it is 
necessary to consider a highly effective and simple to practice anti-HCMV therapeutic strategy. HCMV appears to 
control the PGE 2 synthesis and the expression of COX-2 (Baryawno et al., 2011) in medulloblastomas. 
Valganciclovir and specific COX-2 inhibitors  (Etoricoxib, Celecoxib) are able to prevent HCMV replication and 
to reduce medulloblastoma tumor cell growth in vitro and in vivo (Baryawno et al., 2011). Anti-CMV treatment 
has already reduced the growth of medulloblastoma by 72% in animal model (Baryawno et al., 2011). The 
double-blind Valcyte Treatment of Glioblastoma Patients in Sweden (VIGAS) clinical trial of valganciclovir 
(Söderberg-Nauclér et al., 2013) found that cases receiving at least 6 months of antiviral therapy had an 
significantly increased rate of 2-year survival (50% vs. 20.6%, P<0.001) compared with controls. In fact, an 
optimal treatment of CMV can help to improve the outcome of GBM patient and may focus additionally and 
primarily on ganciclovir or valganciclovir (Söderberg-Nauclér et al., 2013) and other similar drugs. In particular, 
drugs like etanercept, etoricoxib (Hung et al., 2017) and leflunomide (John et al., 2004; Suissa et al., 2006) are 
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simple to work with and are to some extent effective against human cytomegalovirus too. Ganciclovir, 
valganciclovir (Söderberg-Nauclér et al., 2013), etanercept, etoricoxib (Hung et al., 2017) and leflunomide (John 
et al., 2004; Suissa et al., 2006) is of strategic importance at least as an add-on therapy in patients suffering from 
glioblastoma multiforme. Thus far, it is useful to point out that John et al. (John et al., 2004) documented the 
efficacy of leflunomide in humans with CMV disease who received loading dose of 100 mg of leflunomide once 
daily on days 1–3 and then 20 mg once daily for three months. To date and for preliminary purposes, Etanercept, 
etoricoxib and leflunomide should become additionally one part of an effective intervention against glioblastoma 
multiforme. We see the bright colors and the beauty of galaxies so far away from our earth and listen very carefully 
to the heartbeat of deep space. I stubbornly refuse to accept the conclusions that we are unable to develop a low 
cost and highly effective vaccine (Inoue et al., 2018) against a CMV infection and even an appropriate DNA CMV 
therapeutic vaccine too. Historically this hope arises out of the experience that together we have achieved what 
divided was impossible. In addition, such an undertaking is an urgent and major public health duty too. 
5. Conclusion 
The studies presented in this publication provided a very impressive evidence of a cause effect relationship 
between HCMV and GBM. In any case, this publication invites us in an overwhelmingly plausible manner to leave 
aside any doubts and any uncertainty we might have about whether there is a cause effect relationship between 
HCMV and GBM. For a different view, until a contrary and more convincing experimental objections have been 
raised against the causal relationship between HCMV and GBM, according to this analysis it is necessary and 
justified to accept in agreement with the majority of studies presented that human cytomegalovirus is the cause of 
glioblastoma multiforme.  
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